[{"id":"02c0c762-6bf3-44e2-9307-0d5b57b009f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440436","created_at":"2021-01-18T21:22:26.561Z","updated_at":"2024-07-02T16:36:37.694Z","phase":"Phase 1/2","brief_title":"Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients","source_id_and_acronym":"NCT04440436","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD19 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • IM19 CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 06/04/2022","primary_completion_date":" 06/04/2022","study_txt":" Completion: 06/04/2035","study_completion_date":" 06/04/2035","last_update_posted":"2020-12-08"}]